
ScienceMore in Science→
Alzheimer’s Drug Candidate Targets DNA Damage and Inflammation
Key Takeaways
- KCL-286 was reported to repair DNA damage and reduce inflammation in an Alzheimer’s mouse model.
- The orally available compound was originally developed for spinal cord injuries.
- It has completed Phase 1 safety and tolerability trials, but has not yet shown effectiveness for Alzheimer’s in humans.
DE
DT Editorial Team··via sciencedaily.com

